X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (5404) 5404
pharmacology & pharmacy (3428) 3428
male (3109) 3109
female (2503) 2503
animals (2161) 2161
cytochrome p-450 cyp3a - genetics (2007) 2007
cytochrome p-450 enzyme system - genetics (1956) 1956
cytochrome p-450 (1815) 1815
adult (1765) 1765
cytochrome p-450 enzyme system - metabolism (1749) 1749
metabolism (1739) 1739
cytochrome p-450 cyp3a (1677) 1677
pharmacokinetics (1639) 1639
middle aged (1529) 1529
genotype (1420) 1420
cytochrome p-450 cyp3a - metabolism (1419) 1419
cytochrome p450 (1148) 1148
pharmacogenetics (986) 986
enzymes (985) 985
expression (963) 963
drug interactions (962) 962
aged (924) 924
toxicology (901) 901
liver (858) 858
physiological aspects (850) 850
rats (841) 841
cyp3a4 (773) 773
research (768) 768
analysis (755) 755
in-vitro (744) 744
genetic aspects (716) 716
liver - enzymology (701) 701
polymorphism, genetic (701) 701
biochemistry & molecular biology (668) 668
induction (662) 662
mice (646) 646
aryl hydrocarbon hydroxylases - genetics (642) 642
p-glycoprotein (624) 624
dose-response relationship, drug (602) 602
liver - metabolism (592) 592
young adult (560) 560
pharmacology/toxicology (552) 552
polymorphism, single nucleotide (551) 551
genetic polymorphisms (528) 528
polymorphism (525) 525
metabolites (519) 519
gene expression (516) 516
microsomes, liver - enzymology (511) 511
drug metabolism (501) 501
pharmacology (499) 499
adolescent (492) 492
rna, messenger - metabolism (490) 490
liver - drug effects (489) 489
tacrolimus (479) 479
cytochrome (471) 471
drug-metabolism (465) 465
cyp3a5 (452) 452
oncology (449) 449
phenotype (444) 444
aryl hydrocarbon hydroxylases - metabolism (440) 440
identification (437) 437
microsomes, liver - metabolism (430) 430
alleles (429) 429
human liver-microsomes (429) 429
cancer (425) 425
area under curve (420) 420
inhibition (419) 419
biotransformation (416) 416
pregnane x receptor (411) 411
cytochrome p-450 enzyme system - biosynthesis (408) 408
aryl hydrocarbon hydroxylases (407) 407
gene-expression (406) 406
cyp3a (395) 395
kinetics (388) 388
cytochrome p-450 cyp2d6 - genetics (382) 382
genes (377) 377
rna, messenger - genetics (377) 377
rats, sprague-dawley (375) 375
cytochrome p-450 enzyme inhibitors (371) 371
health aspects (371) 371
hydroxylation (371) 371
polymorphisms (369) 369
cells, cultured (367) 367
transplantation (359) 359
pregnane-x-receptor (349) 349
biomedicine (348) 348
drug-interactions (348) 348
immunosuppressive agents - pharmacokinetics (348) 348
drugs (345) 345
mixed function oxygenases - genetics (345) 345
hepatocytes - drug effects (340) 340
microsomes, liver - drug effects (328) 328
mixed function oxygenases - metabolism (326) 326
enzyme inhibitors - pharmacology (322) 322
administration, oral (319) 319
midazolam (317) 317
cytochrome-p450 (315) 315
hepatocytes - metabolism (310) 310
receptors, steroid - metabolism (308) 308
medicine & public health (307) 307
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (6979) 6979
Japanese (103) 103
Chinese (55) 55
Spanish (10) 10
Russian (8) 8
German (6) 6
Polish (4) 4
Czech (2) 2
French (2) 2
Hungarian (2) 2
Romanian (1) 1
Slovak (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
Drug metabolism and disposition, ISSN 1521-009X, 2010, Volume 38, Issue 1, pp. 92 - 99
The aim of the current study is to identify the human cytochrome P450 (P450) isoforms involved in the two oxidative steps in the bioactivation of clopidogrel... 
MECHANISM-BASED INHIBITION | ANTIAGGREGATING ACTIVITY | POLYMORPHISMS | PHARMACOKINETICS | TICLOPIDINE | PHARMACOLOGY & PHARMACY | PRASUGREL | PHARMACODYNAMICS | MONOCLONAL-ANTIBODIES | Microsomes - metabolism | Humans | Aryl Hydrocarbon Hydroxylases - genetics | Cytochrome P-450 Enzyme System - metabolism | Sulfaphenazole - pharmacology | Microsomes - drug effects | Cytochrome P-450 CYP3A - genetics | Cytochrome P-450 CYP1A2 - genetics | Antibodies - immunology | Omeprazole - pharmacology | Microsomes, Liver - enzymology | Platelet Aggregation Inhibitors - pharmacokinetics | Ticlopidine - pharmacokinetics | Oxidoreductases, N-Demethylating - metabolism | Aryl Hydrocarbon Hydroxylases - immunology | Oxidation-Reduction | Enzyme Inhibitors - pharmacology | Ticlopidine - analogs & derivatives | Oxidoreductases, N-Demethylating - immunology | Cytochrome P-450 CYP3A - metabolism | Cell Line, Tumor | Cytochrome P-450 Enzyme System - genetics | Theophylline - pharmacology | Kinetics | Cytochrome P-450 CYP2C9 | Theophylline - analogs & derivatives | Oxidoreductases, N-Demethylating - genetics | Glutathione - metabolism | Ketoconazole - pharmacology | Biotransformation - physiology | Cytochrome P-450 CYP1A2 Inhibitors | Microsomes, Liver - drug effects | Ticlopidine - metabolism | NADP - metabolism | Platelet Aggregation Inhibitors - metabolism | Cytochrome P-450 CYP3A - immunology | Cell Line | Aryl Hydrocarbon Hydroxylases - antagonists & inhibitors | Cytochrome P-450 CYP1A2 - immunology | Biocatalysis | Mephenytoin - analogs & derivatives | Cytochrome P-450 CYP1A2 - metabolism | Aryl Hydrocarbon Hydroxylases - metabolism | Mephenytoin - pharmacology | Antibodies - pharmacology | Cytochrome P-450 CYP3A Inhibitors | Cytochrome P-450 CYP2C19 | Clopidogrel | Cytochrome P-450 CYP2B6
Journal Article
PLoS ONE, ISSN 1932-6203, 04/2014, Volume 9, Issue 4, p. e93261
Intratumoral expression of genes encoding Cytochrome P450 enzymes (CYP) might play a critical role not only in cancer development but also in the metabolism of... 
CYP3A4/5 | CYP2W1 | METABOLISM | CANCER | MULTIDISCIPLINARY SCIENCES | CHILDREN | Cytochrome P-450 CYP1A1 - genetics | Cytochrome P-450 CYP1B1 - genetics | Prospective Studies | Follow-Up Studies | Humans | Rhabdomyosarcoma - metabolism | Gene Expression Regulation, Neoplastic | Child, Preschool | Cytochrome P-450 Enzyme System - metabolism | Cytochrome P-450 CYP1B1 - metabolism | Infant | Male | Muscle, Skeletal - metabolism | Cytochrome P-450 CYP2E1 - genetics | Gene Expression Profiling | Cytochrome P-450 CYP2E1 - metabolism | Cytochrome P450 Family 2 | Cytochrome P-450 CYP3A - genetics | Cytochrome P-450 CYP1A2 - genetics | Biomarkers, Tumor - metabolism | Female | Child | Real-Time Polymerase Chain Reaction | RNA, Messenger - genetics | Cytochrome P-450 CYP1A1 - metabolism | Reverse Transcriptase Polymerase Chain Reaction | Cytochrome P-450 CYP1A2 - metabolism | Blotting, Western | Gene Expression Regulation, Enzymologic | Cytochrome P-450 CYP3A - metabolism | Adolescent | Cytochrome P-450 Enzyme System - genetics | Biomarkers, Tumor - genetics | Rhabdomyosarcoma - genetics | Cytochrome | Drugs | Rhabdomyosarcoma | Chemoresistance | Families & family life | Drug development | Tissues | Cancer therapies | Antitumor agents | Rodents | Drug metabolism | Children | Enzymes | Prodrugs | Cytochrome P450 | CYP gene | CYP1A2 protein | Metabolism | Gene expression | Chemical compounds | Patients | Polymerase chain reaction | Musculoskeletal system | Chemotherapy | Tumors | Cancer
Journal Article
International journal of nanomedicine, ISSN 1178-2013, 2018, Volume 13, pp. 8561 - 8575
Introduction and objective: Currently, carbon nanostructures are vastly explored materials with potential for future employment in biomedicine. The possibility... 
Nanoparticles | Carbon nanostructures | Cytochrome p450 | Liver | Microsomes | liver | POLYCYCLIC AROMATIC-HYDROCARBONS | NANOMATERIALS | NANOSCIENCE & NANOTECHNOLOGY | TOXICITY | carbon nanostructures | cytochrome P450 | INDUCTION | DRUG-METABOLIZING-ENZYMES | WALLED CARBON NANOTUBES | nanoparticles | HEPG2 CELLS | PHARMACOLOGY & PHARMACY | EXPRESSION | CYTOCHROME-P450 ENZYME | microsomes | Cytochrome P-450 CYP2D6 - genetics | Nanostructures - ultrastructure | Cytochrome P-450 Enzyme Inhibitors | Cell Survival | Humans | Liver - metabolism | Cytochrome P-450 Enzyme System - metabolism | Fluorescence | Hydrodynamics | Hepatocytes - metabolism | Diamond - chemistry | Cytochrome P-450 CYP1A2 - metabolism | Down-Regulation - genetics | Hep G2 Cells | Cytochrome P-450 CYP3A - genetics | Cytochrome P-450 CYP3A - metabolism | Isoenzymes - metabolism | Cytochrome P-450 CYP1A2 - genetics | Cytochrome P-450 CYP2D6 - metabolism | Cytochrome P-450 Enzyme System - genetics | Nanostructures - chemistry | Graphite - chemistry | Cytochrome P-450 Enzyme System - pharmacology | Hepatocytes - drug effects | Diamond crystals | RNA | Isoenzymes | Graphene | Genes | Cytochrome P-450 | Diamonds | Graphite | Genetic research | Genetic aspects | Gene expression | Cytochrome | Enzymes | Drug delivery systems | Nanomaterials | Metabolism | Carbon | Drug dosages
Journal Article
Alcoholism: Clinical and Experimental Research, ISSN 0145-6008, 01/2016, Volume 40, Issue 1, pp. 73 - 82
Background Our recent study has shown that acute treatment with ethanol (EtOH) increases oxidative stress and cytotoxicity through cytochrome P450 2E1... 
Cytochrome P450s | Darunavir/Ritonavir | Ethanol | Oxidative Stress | Antioxidant Enzymes | Oxidative stress | Antioxidant enzymes | DENDRITIC CELLS | MACROPHAGES | SUBSTANCE ABUSE | PROTEASE INHIBITORS | NICOTINE METABOLITES | HIV | ALCOHOL | LC-MS/MS METHOD | CONCURRENT DETERMINATION | DRUG-DRUG INTERACTIONS | RITONAVIR | Catalase - drug effects | Superoxide Dismutase - genetics | Antioxidants - metabolism | Humans | Cytochrome P-450 Enzyme System - metabolism | Monocytes - metabolism | Cytochrome P-450 CYP2E1 - genetics | Cytochrome P-450 CYP2E1 - metabolism | RNA, Messenger - metabolism | Peroxiredoxin VI - genetics | Central Nervous System Depressants - pharmacology | HIV Protease Inhibitors - pharmacology | Peroxiredoxin VI - metabolism | Darunavir - pharmacology | Cytochrome P-450 CYP3A - genetics | Cytochrome P-450 CYP2E1 - drug effects | Ritonavir - pharmacology | Cytochrome P-450 CYP3A - drug effects | Superoxide Dismutase - metabolism | RNA, Messenger - drug effects | Cell Line | Cell Survival - drug effects | Catalase - genetics | Oxidative Stress - genetics | Peroxiredoxin VI - drug effects | Reverse Transcriptase Polymerase Chain Reaction | Superoxide Dismutase - drug effects | Blotting, Western | Catalase - metabolism | Monocytes - drug effects | Cytochrome P-450 Enzyme System - drug effects | Ethanol - pharmacology | Cytochrome P-450 CYP3A - metabolism | Cytochrome P-450 Enzyme System - genetics | Oxidative Stress - drug effects | Superoxide Dismutase-1 | Antioxidants | Antiviral agents | Alcohol, Denatured | RNA | Analysis | Cytochrome P-450 | Physiological aspects | HIV patients | Alcohol | darunavir | antioxidant enzymes | cytochrome P450s | oxidative stress | ritonavir
Journal Article
British Journal of Pharmacology, ISSN 0007-1188, 06/2010, Volume 160, Issue 4, pp. 919 - 930
Background and purpose:  The major drug-metabolizing enzymes for the oxidation of oxycodone are CYP2D6 and CYP3A... 
CYP3A | drug-drug interactions | CYP2D6 | pharmacodynamics | oxycodone | oxymorphone | experimental pain | genetic polymorphism | drug–drug interactions | Pharmacodynamics | Oxycodone | Genetic polymorphism | Experimental pain | Drug-drug interactions | Oxymorphone | MORPHINE | RIFAMPIN | RELEASE | PAIN | PHARMACOKINETICS | IN-VIVO | PHARMACOLOGY & PHARMACY | PHARMACOGENETICS | CODEINE | RECEPTOR-BINDING | Cytochrome P-450 CYP2D6 Inhibitors | Humans | Middle Aged | Analgesics, Opioid - pharmacology | Male | Young Adult | Analgesics, Opioid - adverse effects | Drug Interactions | Pain Threshold - drug effects | Adult | Oxycodone - adverse effects | Metabolic Detoxication, Phase I - genetics | Oxymorphone - blood | Cytochrome P-450 CYP2D6 - genetics | Oxycodone - therapeutic use | Reflex, Pupillary - drug effects | Oxycodone - pharmacology | Double-Blind Method | Enzyme Inhibitors - pharmacology | Analgesics, Opioid - therapeutic use | Genotype | Psychomotor Performance - drug effects | Polymorphism, Genetic | Cross-Over Studies | Oxycodone - pharmacokinetics | Phenotype | Cytochrome P-450 CYP3A Inhibitors | Cytochrome P-450 CYP3A - metabolism | Analgesics, Opioid - pharmacokinetics | Cytochrome P-450 CYP2D6 - metabolism | Drug therapy | Enzymes | Pain | Pain perception | Ketoconazole | Toxicity | Cytochrome P450 | Gene polymorphism | Electrical stimuli | Side effects | Analgesics | Metabolites | Quinidine | Drug interaction | Oxidation | Pharmacokinetics | CYP2D6 protein | Research Papers
Journal Article
British Journal of Pharmacology, ISSN 0007-1188, 06/2010, Volume 160, Issue 4, pp. 907 - 918
Journal Article
PLoS ONE, ISSN 1932-6203, 09/2015, Volume 10, Issue 9, pp. e0138875 - e0138875
.... The expression levels of CYP3A and CYP1A mRNA were analyzed by the real time polymerase chain reaction (RT-PCR) technique... 
VITRO | COCKTAIL | METABOLISM | DRUG-INTERACTIONS | HUMAN HEPATOCYTES | MULTIDISCIPLINARY SCIENCES | IN-VIVO | INDUCTION | Cytochrome P-450 CYP1A2 Inducers - pharmacology | Cells, Cultured | Male | Cytochrome P-450 CYP1A2 - metabolism | Rats, Sprague-Dawley | Quinolines - pharmacology | Cytochrome P-450 CYP1A2 Inducers - pharmacokinetics | Quinolines - pharmacokinetics | Animals | Cytochrome P-450 CYP3A Inducers - pharmacology | Cytochrome P-450 CYP3A - genetics | Cytochrome P-450 CYP3A - metabolism | Cytochrome P-450 CYP1A2 - genetics | Cytochrome P-450 CYP3A Inducers - pharmacokinetics | Enzyme Induction - drug effects | Antineoplastic Agents - pharmacokinetics | Antineoplastic Agents - pharmacology | Kinetics | Hepatocytes - drug effects | Hepatocytes - enzymology | Complications and side effects | Chemotherapy | Cytochrome P-450 | Physiological aspects | Quinoline | Genetic aspects | Dosage and administration | Research | Cancer | Cytochrome | CYP1A protein | Life assessment | mRNA | Cancer therapies | Toxicology | Metabolites | Rodents | Pretreatment | Inducers | Caffeine | Enzymes | Cytochrome P450 | Rats | Pharmacology | Liquid chromatography | FDA approval | Metabolism | Gene expression | High-performance liquid chromatography | Polymerase chain reaction | Studies | Pathology | Hepatocytes | Pharmacy | In vivo methods and tests | Pharmaceuticals | Index Medicus
Journal Article
Pharmacogenetics and Genomics, ISSN 1744-6872, 08/2013, Volume 23, Issue 8, pp. 403 - 414
Journal Article
Clinical Chemistry, ISSN 0009-9147, 10/2009, Volume 55, Issue 10, pp. 1770 - 1782
.... The polymorphic CYP2D6 is the key enzyme in this biotransformation, and recent mechanistic, pharmacologic, and clinical evidence suggests that genetic variants and drug interaction by CYP2D6... 
UDP-GLUCURONOSYLTRANSFERASE 1A4 | IN-VITRO | ADJUVANT ENDOCRINE THERAPY | BREAST-CANCER PATIENTS | HUMAN LIVER-MICROSOMES | MEDICAL LABORATORY TECHNOLOGY | CYTOCHROME P4502C9 POLYMORPHISMS | AMMONIUM-LINKED GLUCURONIDATION | ALPHA-HYDROXYTAMOXIFEN | ESTROGEN-RECEPTOR | HOT FLASHES | Cytochrome P-450 CYP2C9 | Neoplasms, Hormone-Dependent - metabolism | Oxidoreductases, N-Demethylating - genetics | Humans | Aryl Hydrocarbon Hydroxylases - genetics | Antineoplastic Agents, Hormonal - metabolism | Breast Neoplasms - metabolism | Genetic Variation | Antineoplastic Agents, Hormonal - adverse effects | Cytochrome P-450 CYP3A - genetics | Antineoplastic Agents, Hormonal - therapeutic use | Female | Oxidoreductases, N-Demethylating - metabolism | Tamoxifen - metabolism | Cytochrome P-450 CYP2D6 - genetics | Pharmacogenetics | Breast Neoplasms - drug therapy | Aryl Hydrocarbon Hydroxylases - metabolism | Cytochrome P-450 CYP2C19 | Cytochrome P-450 CYP3A - metabolism | Tamoxifen - therapeutic use | Cytochrome P-450 CYP2D6 - metabolism | Neoplasms, Hormone-Dependent - drug therapy | Tamoxifen - adverse effects | Cytochrome P-450 CYP2B6 | Studies | Genotype & phenotype | Womens health | Mortality | Clinical trials | Breast cancer | Cancer therapies | Patients | Clinical outcomes | Index Medicus
Journal Article